news
Abbott’s HUMIRA® (adalimumab) approved in Europe for treatment of non-radiographic axial spondyloarthritis
The European Commission has approved HUMIRA®...
30 July 2012 | By Abbott
The European Commission has approved HUMIRA®...
List view / Grid view
John Leonard
news
Abbott receives positive opinion for HUMIRA® in non-radiographic axial spondyloarthritis from EMA’s CHMP
Abbott announced that the CHMP has issued a positive opinion…
25 June 2012 | By Abbott
Abbott announced that the CHMP has issued a positive opinion for HUMIRA®...
news
Abbott’s HUMIRA® (adalimumab) approved in Europe for treatment of ulcerative colitis (UC)
The European Commission has approved HUMIRA®...
11 April 2012 | By
The European Commission has approved HUMIRA®...
news
Abbott and Galapagos announce global collaboration for novel oral therapy, GLPG0634, in Phase II
Abbott and Galapagos have entered into a global collaboration...
29 February 2012 | By Abbott
Abbott and Galapagos have entered into a global collaboration...
news
Abbott receives positive opinion for HUMIRA® in Ulcerative Colitis from EMA’s CHMP
Positive opinion based on supporting data from two Phase III…
17 February 2012 | By Abbott
Positive opinion based on supporting data from two Phase III clinical studies...
news
DNDi and Abbott expand partnership to boost innovation for neglected tropical diseases
DNDi & Abbott have signed a four-year joint research &…
30 January 2012 | By Abbott
DNDi & Abbott have signed a four-year joint research & non-exclusive licensing agreement...
news
Abbott and Reata Pharmaceuticals announce agreement to develop and commercialize next-generation AIMs
Agreement calls for 50/50 global profit share for multiple new…
12 December 2011 | By Abbott
Agreement calls for 50/50 global profit share for multiple new molecules...
news
Abbott statement on the results of the AIM-HIGH study presented at AHA 2011
Final results were presented today from the AIM-HIGH study, a…
15 November 2011 | By Abbott
Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study...
news
Abbott presents HUMIRA® (adalimumab) Phase 3 study results
In ABILITY-1 Study Presented at ACR, More than Twice as…
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
news
Abbott announces new long-term data evaluating sse of HUMIRA® (Adalimumab) for patients with long-standing moderate to severe Rheumatoid Arthritis and for patients with early moderate to severe RA
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
5 November 2011 | By Abbott
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
article
eLN supplement 2011
In this eLN supplement: eLNs - An essential productivity tool…
In this eLN supplement: eLNs - An essential productivity tool - but which one to use?; Using an eLN to create GMP compliant records for drug substance manufacture; Implementation of an electronic lab notebook system at VIB; eLN roundtable...
